Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [F-18]FDG: version 1.0

• Authors: Ian Law, University of Copenhagen; Nathalie L. Albert, Ludwig-Maximilians-University; Javier Arbizu, University of Navarra; Ronald Boellaard, University Medical Center Groningen; Alexander Drzezga, University Hospital Cologne; Norbert Galldiks, University Hospital Cologne; Christian la Fougere, University of Tübingen; Karl-Josef Langen, Forschungszentrum Julich; Egesta Lopci, Humanitas Clinical and Research Hospital; Val Lowe, Mayo Clinic; Jonathan McConathy, University of Alabama Birmingham; Harald H. Quick, University Hospital Essen; Bernhard Sattler, University Hospital Leipzig; David M Schuster, Emory University; Jörg-Christian Tonn, Ludwig-Maximilians-University Munich; Michael Weller, University Hospital Zurich
• Journal Title: European Journal of Nuclear Medicine and Molecular Imaging
• Volume: Volume 46, Number 3
• Publisher: Springer Verlag (Germany) | 2019-03-01, Pages 540-557
• Type of Work: Article | Final Publisher PDF
• Publisher DOI: http://doi.org/10.1007/s00259-018-4207-9
• Keywords: Science & Technology; Life Sciences & Biomedicine; Radiology, Nuclear Medicine & Medical Imaging; FDG; FET; MET; FDOPA; PET; Glioma; POSITRON-EMISSION-TOMOGRAPHY; RECURRENT MALIGNANT GLIOMA; EANM PROCEDURE GUIDELINES; CENTRAL-NERVOUS-SYSTEM; HIGH-GRADE; O-(2-F-18-FLUOROETHYL)-L-TYROSINE PET; ATTENUATION CORRECTION; BRAIN-TUMORS; F-18-FET PET; C-11-METHIONINE PET

Abstract

These joint practice guidelines, or procedure standards, were developed collaboratively by the European Association of Nuclear Medicine (EANM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of Neurooncology (EANO), and the working group for Response Assessment in Neurooncology with PET (PET-RANO). Brain PET imaging is being increasingly used to supplement MRI in the clinical management of glioma. The aim of these standards/guidelines is to assist nuclear medicine practitioners in recommending, performing, interpreting and reporting the results of brain PET imaging in patients with glioma to achieve a high-quality imaging standard for PET using FDG and the radiolabelled amino acids MET, FET and FDOPA. This will help promote the appropriate use of PET imaging and contribute to evidence-based medicine that may improve the diagnostic impact of this technique in neurooncological practice. The present document replaces a former version of the guidelines published in 2006 (Vander Borght et al. Eur J Nucl Med Mol Imaging. 33:1374–80, 2006), and supplements a recent evidence-based recommendation by the PET-RANO working group and EANO on the clinical use of PET imaging in patients with glioma (Albert et al. Neuro Oncol. 18:1199–208, 2016). The information provided should be taken in the context of local conditions and regulations.